Carregant...
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/165519
Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections.
Matèries
Matèries (anglès)
Citació
Citació
MONTEIL, Vanessa, KWON, Hyesoo, PRADO, Patricia, HAGELKRÜYS, Astrid, WIMMER, Reiner a., STAHL, Martin, LEOPOLDI, Alexandra, GARRETA, Elena, HURTADO DEL POZO, Carmen, PROSPER, Felipe, ROMERO, Juan pablo, WIRNBERGER, Gerald, ZHANG, Haibo, SLUTSKY, Artur s., CONDER, Ryan, MONTSERRAT, Núria, MIRAZIMI, Ali, PENNINGER, Josef m.. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. _Cell_. 2020. Vol. 181, núm. 4, pàgs. 905-913. [consulta: 25 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/165519]